Trial Profile
An open-label, Proof-of-Concept trial in treatment-naive HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy.
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2012
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Janssen R&D Ireland
- 19 Jul 2011 New trial record